Research summary ·
Efficacy and safety of Ginkgo biloba leaf extract injection for vascular cognitive impairment: a systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This review looked at a drug called Shuxuening injection, or SXNI. It is made from Ginkgo biloba leaf extract. It is given as a shot. The review was about people with vascular cognitive impairment. The team pooled results from randomized trials. The search covered trials published before 1 September 2025. In these trials, one group got usual care. The other group got usual care plus SXNI. The main result was a score on a test of thinking skills.
What they found
The trials held 2,375 people in total. All trials took place in China, from 2005 to 2025. Adding SXNI was linked to higher scores on thinking tests. It was also linked to better scores on a test of daily tasks. It was linked to lower scores on a stroke scale too. The SXNI group also had a higher overall response rate. Only some trials reported side effects. In those trials, side effects were not clearly more common with SXNI.
What it means for patients
The authors say adding SXNI to usual care may help thinking. It may also help nerve function and daily tasks. Reported side effects did not clearly go up with SXNI.
Why it is not certain yet
The authors say the evidence is not very certain. The trials had weak points in how they were done. SXNI from different makers may not be the same. The authors say better studies are needed to check these results. A review can only be as good as the studies in it.
Source
Efficacy and safety of Ginkgo biloba leaf extract injection for vascular cognitive impairment: a systematic review and meta-analysis.
PubMed · PMID 42051256We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Vascular dementia publications